Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

  • The following terms were not found in PubMed: porsch-markus[author], janitzky-andreas[author], grube-christian[author], blaschke-simon[author], kreutze-sebastian[author], schindele-daniel[author], sulldorf-m[author], ulrich-matthias[author].
1.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Aug 9. pii: S1470-2045(19)30412-7. doi: 10.1016/S1470-2045(19)30412-7. [Epub ahead of print]

PMID:
31405822
2.

Awareness and perception of multidrug-resistant organisms and antimicrobial therapy among internists vs. surgeons of different specialties: Results from the German MR2 Survey.

Spachmann PJ, May M, Vetterlein MW, Fritsche HM, Steffen S, Schostak M, Wagenlehner FM, Burger M, Weylandt KH, Salzberger B, Brookman-May SD, Gilfrich C; MR2 study group.

Caspian J Intern Med. 2019 Spring;10(2):132-141. doi: 10.22088/cjim.10.2.132.

3.

Prospective evaluation of CT-guided HDR brachytherapy as a local ablative treatment for renal masses: a single-arm pilot trial.

Damm R, Streitparth T, Hass P, Seidensticker M, Heinze C, Powerski M, Wendler JJ, Liehr UB, Mohnike K, Pech M, Ricke J.

Strahlenther Onkol. 2019 Jul 25. doi: 10.1007/s00066-019-01501-1. [Epub ahead of print]

PMID:
31346674
4.

How well do software assistants for minimally invasive partial nephrectomy meet surgeon information needs? A cognitive task analysis and literature review study.

Joeres F, Schindele D, Luz M, Blaschke S, Russwinkel N, Schostak M, Hansen C.

PLoS One. 2019 Jul 18;14(7):e0219920. doi: 10.1371/journal.pone.0219920. eCollection 2019.

5.

Erratum zu: Therapiesituation beim metastasierten kastrationsnaiven Prostatakarzinom (mCNPC) und die Auswirkungen im klinischen Alltag.

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Aug;58(8):924. doi: 10.1007/s00120-019-0985-3. German. No abstract available.

PMID:
31236656
6.

[The Onkonet database: taking stock of an Internet-based, multi-centre database on surgical prostate cancer treatment].

Pohle M, Magheli A, Diederichs W, Ecke T, Fischer T, Kempkensteffen C, Knispel H, Lehsnau M, Miller K, Pretzer J, Schostak M, Winter A, Zacharias M, Hinz S.

Aktuelle Urol. 2019 Jun 13. doi: 10.1055/a-0919-3993. [Epub ahead of print] German.

PMID:
31195415
7.

Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy.

Omari J, Heinze C, Damm R, Hass P, Janitzky A, Wendler JJ, Seidensticker M, Ricke J, Powerski MJ, Pech M.

Anticancer Res. 2019 May;39(5):2501-2508. doi: 10.21873/anticanres.13370.

PMID:
31092445
8.

[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Apr 30. doi: 10.1007/s00120-019-0925-2. [Epub ahead of print] Review. German. Erratum in: Urologe A. 2019 Aug;58(8):924.

PMID:
31041460
9.

[Focal therapy in prostate cancer : Five-year outcome].

Schindele D, Schostak M.

Urologe A. 2019 May;58(5):562-563. doi: 10.1007/s00120-019-0902-9. German. No abstract available.

PMID:
30953091
10.

Small renal carcinoma: the "when" and "how" of operation, active surveillance, and ablation.

Wendler JJ, Liehr BU, Damm R, Powerski M, Brunner T, Schostak M, Pech M.

Pol J Radiol. 2018 Dec 22;83:e561-e568. doi: 10.5114/pjr.2018.81282. eCollection 2018. Review.

11.

[Focal therapy for prostate cancer].

Schostak M.

Urologe A. 2019 May;58(5):518-523. doi: 10.1007/s00120-019-0862-0. Review. German.

PMID:
30734839
12.

The natural history of renal cell carcinoma with pulmonary metastases illuminated through mathematical modeling.

Hanin L, Jandrig B, Pavlova L, Seidel K.

Math Biosci. 2019 Mar;309:118-130. doi: 10.1016/j.mbs.2019.01.008. Epub 2019 Jan 28.

PMID:
30703380
13.

The importance of sexuality, changes in erectile functioning and its association with self-esteem in men with localized prostate cancer: data from an observational study.

Hilger C, Schostak M, Neubauer S, Magheli A, Fydrich T, Burkert S, Kendel F.

BMC Urol. 2019 Jan 21;19(1):9. doi: 10.1186/s12894-019-0436-x.

14.

Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine.

May M, Schostak M, Lebentrau S; MR2- study group.

Int Urogynecol J. 2019 Feb;30(2):335-336. doi: 10.1007/s00192-018-3851-8. Epub 2018 Dec 18. No abstract available.

PMID:
30564871
15.

Risk Factors for Ureteral Damage in Ureteroscopic stone Treatment: Results of the German Prospective Multicentre Benchmarks of Ureterorenoscopic Stone Treatment-Results in Terms of Complications, Quality of Life, and Stone-Free Rates Project.

Lebentrau S, Müller PF, Miernik A, Schönthaler M, Gilfrich C, Peter J, Schostak M, May M; BUSTER study group.

Urol Int. 2019;102(2):187-193. doi: 10.1159/000495072. Epub 2018 Nov 27.

PMID:
30481771
16.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

Eur Urol. 2019 Apr;75(4):604-611. doi: 10.1016/j.eururo.2018.09.047. Epub 2018 Oct 15.

PMID:
30337060
17.

Studie zur Prädiktion von AR-V7 und CTC-Zirkulation bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC).

Rexer H, Hammerer P, Schostak M, König F.

Aktuelle Urol. 2018 Sep;49(5):392-393. doi: 10.1055/a-0634-7753. Epub 2018 Sep 5. German. No abstract available.

PMID:
30184595
18.

Hospital volume in ureterorenoscopic stone treatment: 99 operations per year could increase the chance of a better outcome-results of the German prospective multicentre BUSTER project.

Lebentrau S, Enzmann T, Lehsnau M, Christoph F, Schostak M, May M; BUSTER study group.

World J Urol. 2019 Apr;37(4):743-749. doi: 10.1007/s00345-018-2431-3. Epub 2018 Aug 9.

PMID:
30094717
19.

Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.

von Hardenberg J, Westhoff N, Baumunk D, Hausmann D, Martini T, Marx A, Porubsky S, Schostak M, Michel MS, Ritter M.

Urol Oncol. 2018 Sep;36(9):401.e1-401.e9. doi: 10.1016/j.urolonc.2018.05.022. Epub 2018 Aug 6.

PMID:
30093211
20.

Impact of surgeon's experience on outcome parameters following ureterorenoscopic stone removal.

Wolff I, Lebentrau S, Miernik A, Ecke T, Gilfrich C, Hoschke B, Schostak M, May M; BUSTER study group.

Urolithiasis. 2018 Jul 4. doi: 10.1007/s00240-018-1073-7. [Epub ahead of print]

PMID:
29974193

Supplemental Content

Loading ...
Support Center